Pubblicazioni

Autori:

Janson, Christer; Malinovschi, Andrei; Amaral, Andre F S; Accordini, Simone; Bousquet, Jean; Buist, Sonia A; Canonica, Giorgio Walter; Dahlén, Barbro; Garcia-Aymerich, Judith; Gnatiuc, Louisa; Kowalski, Marek L; Patel, Jaymini; Tan, Wan; Torén, Kjell; Zuberbier, Torsten; Burney, Peter; Jarvis, Deborah

---

Titolo:

Bronchodilator reversibility in asthma and COPD: findings from three large population studies

---

Anno:

2019

---

Tipologia prodotto:

Articolo in Rivista

---

Tipologia ANVUR:

Articolo su rivista

---

Lingua:

Inglese

---

Formato:

Elettronico

---

Referee:

Sì

---

Nome rivista:

European Respiratory Journal

---

ISSN Rivista:

0903-1936

---

N° Volume:

54

---

Numero o Fascicolo:

3

---

Intervallo pagine:

1-11

---

Parole chiave:

asthma, BOLD, bronchodilator reversibility, COPD, ECRHS, GA2LEN, prevalence

---

Breve descrizione dei contenuti:

Bronchodilator response (BDR) testing is used as a diagnostic method in obstructive airway diseases. The aim of this investigation was to compare different methods for measuring BDR in participants with asthma and COPD and to study to the extent to which BDR was related to symptom burden and phenotypic characteristics.Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) was measured before and 15 min after 200 μg of salbutamol in 35 628 subjects aged 16 years and older from three large international population studies. The subjects were categorised in three groups: current asthma (n=2833), COPD (n=1146), and no airway disease (n=31 649). Three definitions for flow related (increase in FEV1) and three for volume related (increase in FVC) were used.The prevalence of bronchodilator reversibility expressed as increase FEV1≥12% and 200 mL was 17.3% and 18.4% in participants with asthma and COPD, respectively, while the corresponding prevalence was 5.1% in those with no airway disease. In asthma, bronchodilator reversibility was associated with wheeze (OR (95% CI): 1.36 (1.04-1.79)), atopy (OR 1.36 (1.04-1.79)) and higher FeNO while in COPD neither flow nor volume related bronchodilator reversibility was associated with symptom burden, exacerbations or health status after adjusting for prebronchodilator FEV1.Bronchodilator reversibility was at least as common in participants with COPD as those with asthma. This indicates that measures of reversibility are of limited value for distinguishing asthma from COPD in population studies. In asthma, however, bronchodilator reversibility may be a phenotypic marker.

---

Pagina Web:

https://doi.org/10.1183/13993003.00561-2019

---

Id prodotto:

109012

---

Handle IRIS:

11562/996442

---

ultima modifica:

3 novembre 2022

---

Citazione bibliografica:

Janson, Christer; Malinovschi, Andrei; Amaral, Andre F S; Accordini, Simone; Bousquet, Jean; Buist, Sonia A; Canonica, Giorgio Walter; Dahlén, Barbro; Garcia-Aymerich, Judith; Gnatiuc, Louisa; Kowalski, Marek L; Patel, Jaymini; Tan, Wan; Torén, Kjell; Zuberbier, Torsten; Burney, Peter; Jarvis, Deborah, Bronchodilator reversibility in asthma and COPD: findings from three large population studies «European Respiratory Journal» , vol. 54 , n. 3 , 2019 , pp. 1-11

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo